This conference will assess priorities for medicines access, supply and pricing in the UK. It follows publication of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) agreement between the DHSC, NHS England and ABPI. Launching from January 2024, the five-year scheme aims to control expenditure on branded medicines, support financial sustainability in the NHS, and to promote better patient outcomes and support the growth of the UK life sciences industry.
